AIM ImmunoTech raises ATM capacity to $3.41M

Amid an existing shelf registration, AIM ImmunoTech, Inc. filed a prospectus supplement dated April 10, 2026 to increase the maximum aggregate offering price under its equity distribution agreement with Maxim Group LLC to $3,409,174.

Accepted by SEC EDGAR 04/10/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Amid an existing shelf registration, AIM ImmunoTech, Inc. filed a prospectus supplement dated April 10, 2026 to increase the maximum aggregate offering price under its equity distribution agreement with Maxim Group LLC to $3,409,174. The supplement relies on General Instruction I.B.6 of Form S-3 and notes a public float of $10,227,521 calculated using 8,182,017 shares held by non‑affiliates at $1.25 per share (closing price on February 13, 2026).

The company states it has sold $2,288,758.60 under the instruction during the prior 12 months and is eligible to sell an additional $1,120,415. Sales, if any, may be made as “at the market offerings” through Maxim, which may receive compensation up to 3.0% of gross proceeds. The supplement affirms Maxim will be deemed an underwriter for these sales and that indemnification provisions apply.

Insights

Capital Markets Attorney

Supplement raises ATM capacity to $3.41M under Form S-3 limits.

The supplement increases the permitted aggregate sales under the Equity Distribution Agreement to $3,409,174, invoking General Instruction I.B.6 of Form S-3. It explicitly states prior sales of $2,288,758.60 during the trailing 12 months and an available remaining capacity of $1,120,415.

Sales are described as possible at the market offerings executed by Maxim; Maxim's compensation is up to 3.0% of gross proceeds and Maxim will be deemed an underwriter. The filing preserves customary indemnification and contribution obligations. Timing and pacing of any share sales are not disclosed in this excerpt.

Key Figures

Maximum aggregate offering price: $3,409,174 Public float: $10,227,521 Non‑affiliate shares used in float: 8,182,017 shares +5 more

8 metrics

Maximum aggregate offering price $3,409,174 authorized under the prospectus supplement

Public float $10,227,521 as of April 10, 2026 (calculated using closing price on February 13, 2026)

Non‑affiliate shares used in float 8,182,017 shares shares of outstanding common stock held by non‑affiliates used to calculate public float (closing price on February 13, 2026)

Price used for float calculation $1.25 per share closing price on February 13, 2026

Prior sales in 12 months $2,288,758.60 sold pursuant to General Instruction I.B.6 during the prior 12 months

Remaining eligible sales $1,120,415 additional amount eligible under General Instruction I.B.6

Sales agent fee up to 3.0% compensation to Maxim of gross proceeds under the EDA

Last reported sale price $0.5180 per share last reported sale price on April 9, 2026

Key Terms

Equity Distribution Agreement (EDA), General Instruction I.B.6 of Form S-3, at the market offerings, public float

4 terms

Equity Distribution Agreement (EDA) regulatory

"terms of the Equity Distribution Agreement, as amended, or the EDA, we entered into with Maxim"

General Instruction I.B.6 of Form S-3 regulatory

"Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares"

at the market offerings market

"Sales of our common stock... may be made in sales deemed to be "at the market offerings" as defined in Rule 415"

At-the-market offerings are a way for a company to raise cash by selling newly issued shares directly into the open market at the current trading price through a broker, rather than in a single large sale. Think of it like topping up a gas tank a little at a time at whatever the pump price is; it gives the company flexibility to raise money when conditions are favorable but can increase the number of shares outstanding and dilute existing investors, and frequent or large sales can put downward pressure on the stock price.

public float market

"aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately"

Public float is the total number of a company's shares that are available for trading by the general public. It excludes shares held by company insiders or large stakeholders who are unlikely to sell them easily. This figure helps investors understand how much of the company's stock is actively available, which can influence its liquidity and how easily its price might change.

Offering Details

ATM · $3,409,174

Offering

Offering Type ATM

Securities Offered common stock

Offering Amount $3,409,174

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does AIM (AIM ImmunoTech) authorize with the April 10, 2026 supplement?

Answer: The supplement authorizes offering up to $3,409,174 in common stock under the Equity Distribution Agreement. It increases the maximum aggregate offering price and records prior sales of $2,288,758.60 in the past 12 months.

How was AIM's public float calculated in the supplement?

Answer: Public float is stated as $10,227,521, calculated using 8,182,017 shares held by non‑affiliates at $1.25 per share, the closing price on February 13, 2026. That figure anchors the Form S‑3 limit.

How much additional capital can AIM raise under General Instruction I.B.6 now?

Answer: The supplement states AIM is eligible to sell an additional $1,120,415 of securities pursuant to General Instruction I.B.6 in the 12‑month period referenced. Prior sales of $2,288,758.60 were recorded.

What selling method and fees are disclosed for AIM's offering?

Answer: Sales may be made as "at the market offerings" through Maxim Group LLC under an Equity Distribution Agreement. Maxim's compensation is up to 3.0% of gross proceeds and it will be deemed an underwriter.

Does the supplement state who receives proceeds from the sales?

Answer: The supplement frames the sales as offerings of the company's common stock under the EDA, implying proceeds flow to AIM; the text treats Maxim as sales agent and underwriter for those transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-286319

AMENDMENT NO. 1 DATED APRIL 10, 2026

To Prospectus Supplement dated October 30, 2025

(To Prospectus Dated July 3, 2025)

Up to $3,409,174

AIM IMMUNOTECH INC.

Common Stock

This prospectus supplement supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus supplement dated October 30, 2025, which together with the accompanying prospectus dated July 3, 2025 contained in our Registration Statement on Form S-3 (Registration No. 333-286319), we refer to as the prospectus, relating to the offering, issuance and sale of shares of our common stock, par value $0.001 per share, from time to time through our sales agent, Maxim Group LLC, or Maxim. These sales, if any, will be made pursuant to the terms of the Equity Distribution Agreement, as amended, or the EDA, we entered into with Maxim.

This prospectus supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection with, the prospectus, including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency between the information in the prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. Any information that is modified or superseded in the prospectus shall not be deemed to constitute a part of the prospectus, except as modified or superseded by this prospectus supplement.

As of April 10, 2026, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately $10,227,521, which was calculated based on 8,182,017 shares of our outstanding common stock held by non-affiliates at a price of $1.25 per share, the closing price of our common stock on February 13, 2026. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares pursuant to this prospectus supplement with a value of more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, or $3,409,174. As of the date of this prospectus supplement, we have sold approximately $2,288,758.60 of securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this prospectus supplement, and are therefore eligible to sell up to an additional $1,120,415 of our securities pursuant to General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period so long as our public float remains below $75 million.

We are filing this prospectus supplement to supplement and amend, as of April 10, 2026, the prospectus, as supplemented, to increase the maximum aggregate offering price of our common stock that may be offered, issued and sold under the prospectus, as supplemented and amended by this prospectus supplement, pursuant to the EDA with Maxim to up to approximately $3,409,174.

Our common stock is traded on the NYSE American under the symbol “AIM.” On April 9, 2026, the last reported sale price of our common stock was $0.5180 per share.

Sales of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. Maxim is not required to sell any specific number or dollar amount of securities but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on terms mutually agreed to by Maxim and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The compensation to Maxim for sales of common stock sold pursuant to the EDA will be up to 3.0% of the gross proceeds of any shares of common stock sold under the EDA. In connection with the sale of the common stock on our behalf, Maxim will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Maxim will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Maxim with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-7 of the prospectus supplement dated October 30, 2025, page 3 of the accompanying prospectus and under similar headings in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Maxim Group LLC

The date of this prospectus supplement is April 10, 2026